Story
HUTCHMED Shares Rise on Launch of Global Cancer Drug Trial
Summary
HUTCHMED China announced the start of a global Phase Ia clinical trial for its key oncology drug, HMPL-A830, sending its Hong Kong-listed shares higher despite broader market weakness.
Shares of HUTCHMED China (HCM) rose on Monday after the biopharmaceutical company announced it has initiated the global Phase Ia portion of a clinical trial for its novel cancer therapy, HMPL-A830. The positive investor reaction came despite a challenging environment for the broader Hong Kong market.
Trial Initiation Details
HUTCHMED disclosed on Monday that the first patient was dosed in the trial on September 24, 2026, in China. The study will evaluate HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate.
The trial is focused on patients with unresectable advanced or metastatic solid tumors. The company has previously described this treatment as the centerpiece of its next-generation oncology platform, making the trial's launch a significant milestone for its drug development pipeline.
Strategic Context and GSK Partnership
The announcement follows a key strategic move in early September, when HUTCHMED signed an exclusive development and licensing agreement with pharmaceutical giant GSK. That deal granted GSK the rights to develop and commercialize HMPL-A830 in all territories outside of Greater China.
AdThe initiation of the global trial so soon after the GSK agreement underscores the momentum behind the drug's development program and its potential for international markets.
Market Reaction
In response to the news, HUTCHMED's Hong Kong-listed shares climbed 1.3% to close at HK$22.2 on Monday.
The gain is notable as it contrasts with recent pressure on the broader market. The Hang Seng Index has been weighed down by surging global bond yields and concerns over inflation and interest rates, factors that have broadly dampened investor sentiment toward growth-oriented sectors like healthcare.
Read next
More on Stocks
Gift Nifty 50 Signals Extreme Oversold Conditions Amid Strong Bearish Trend
Technical analysis of Gift Nifty 50 futures shows the index in a clear downtrend, but key momentum indicators like the RSI and MFI have fallen to levels suggesting extreme seller exhaustion, raising the possibility of a sharp price rebound.
Daiichi Sankyo Stock Drops After US Application for Cancer Drug Withdrawn
Shares in the Japanese pharmaceutical company fell after it and partner Merck pulled an application for accelerated FDA approval of an experimental lung cancer therapy, citing insufficient data from a mid-stage trial.
Nidec Shares Plunge on Report of $6.3 Billion Impairment, CEO Dismissal
Shares of Nidec Corp. plummeted, hitting their daily limit down, after a Japanese media report alleged the motor maker plans a massive ¥1 trillion impairment charge and has dismissed its chief executive.
Metrics Credit Partners Halts Three Funds, Slashes Asset Values After Audit Disagreement
Australian private credit manager Metrics Credit Partners has suspended trading in three of its ASX-listed funds and significantly reduced their asset valuations following a disagreement with its auditor, KPMG, over financial assumptions.